Japan has formal rules for regenerative medicine, but there is no single “safe stem cell therapy.” Safety comes down to the exact product or procedure, your diagnosis, how the cells were processed, how they’re given, and what the follow-up plan looks like. A treatment can be legally offered under Japan’s regenerative-medicine rules without being the same as a PMDA-approved product for your condition.
Regulatory information checked August 2026
Public-source verification before payment
Four things to check first
A filed provision plan and PMDA marketing approval are different. Ask which one applies to the exact intervention.
Evidence should match the disease, stage, cell type, dose, route, comparator and follow-up period.
Ask where the cells are processed, what release tests are used and what happens if a batch fails.
Ask who manages an adverse event, what monitoring is scheduled and what care is available after you return home.
Your condition, your answer
Don’t borrow evidence from a different disease, a different cell source, or a different way of giving the treatment.
Hematopoietic stem-cell transplantation has established roles for selected conditions. Survival and complication estimates must be matched to the exact diagnosis, disease status, age, donor source and transplant plan.
Established in selected indicationsJapan granted conditional and time-limited approval in March 2026 to AMCHEPRY, a specific allogeneic iPS-cell-derived dopaminergic progenitor product for a defined Parkinson’s indication. This does not validate unrelated stem-cell products or generic infusions.
Product-specific approvalJapan has product-specific regulatory experience, but timing, injury level, severity and the exact product matter. Chronic injury protocols cannot borrow evidence from a different acute-injury product. Review spinal cord injury evidence.
Human trials suggest some protocols may improve pain or function, but a predictable cure or reliable cartilage regrowth has not been established. Review knee evidence and recovery measures.
There is no valid universal success rate. The exact pain diagnosis, cell source, manufacturing process and route must be checked separately. Review chronic-pain evidence.
The same cell label can refer to very different products and procedures.
What happened in 2026
These events were tied to specific autologous adipose-derived MSC plans for chronic pain. They don’t tell you the risk of every stem-cell therapy out there.
MHLW reported that a foreign patient deteriorated during administration, had cardiac arrest and was later confirmed dead. The cause had not been established when the order was issued. MHLW temporarily stopped the specific plan and certain similarly manufactured cell preparations while the event was investigated. MHLW source
MHLW reported that at least five patients had symptoms including chills, fever and nausea after a related chronic-pain plan, with at least one requiring inpatient care. The ministry also described required reporting and cause-investigation failures and issued another emergency order. MHLW source
Send whatever you’ve got so far. We’ll help get the questions and documents organized before you make up your mind.
What risks to ask about
Risk isn’t one-size-fits-all. It depends on how the cells were collected, how they were processed, where they came from, the route, the dose, and your overall health.
Pain, bleeding, infection, anesthesia-related events or complications from injection or surgery.
Culture, storage, transport and release testing can affect product quality and infection risk.
Fever, allergic or infusion reactions and route-specific vascular or neurological complications can occur.
Risk varies by cell type. Donor cells and pluripotent-cell-derived products require product-specific controls and monitoring.
Anticoagulants, immune suppression, infection risk and unstable medical conditions may change eligibility or procedure risk.
Do not stop standard medication, rehabilitation or other established care unless a qualified treating professional changes the plan.
What it costs, really
We reviewed public self-pay examples in August 2026, and the range is wide. These are asking prices—not an official tariff, and definitely not proof that a treatment works.
Cell source, culture method and included follow-up differ.
About ¥0.95M-¥2.49M
Route, cell plan and diagnosis change the price.
About ¥1.65M-¥3.52M
Some higher-cell-count plans are more expensive.
About ¥2.75M-¥5.94M
Consultation, blood tests, infection screening, imaging and tissue collection.
Culture, quality checks, release testing, storage and failed-batch policy.
Administration route, number of sessions, medicines and monitoring.
Rehabilitation, repeat imaging, follow-up, travel and language support.
Source basis: public self-pay examples reviewed in August 2026. These figures are examples of asking prices, not a national fee schedule.
See the 2026 cost breakdown by condition and routeWhat to measure, what to expect
One “success rate” across all stem-cell therapies doesn’t mean much.
Blood disease / transplant
Track: engraftment, relapse, infection, treatment-related mortality and overall survival.
Recovery: depends on conditioning, donor source, complications and immune recovery.
Neurological conditions
Track: validated motor or function scales, independence and rehabilitation goals.
Recovery: improvement may be gradual and must be separated from rehabilitation effects.
Joint disorders
Track: pain, walking, function, activity and durability.
Recovery: symptom improvement is more useful than a claim of “cartilage regeneration.”
Diabetes and metabolic use
Track: HbA1c, insulin requirement, severe hypoglycemia and durability.
Recovery: do not stop insulin or standard care based on a promotional claim.
Before treatment, record a baseline and agree on what will be measured after treatment.
Can you actually get it?
Active or recent infection; unstable heart, lung, liver or kidney disease; bleeding or clotting risk; immune suppression; pregnancy; cancer history; and medicines that affect the planned procedure.
This is not a universal exclusion list. The exact protocol sets its own criteria.
Exact diagnosis and stage, symptom duration, recent imaging and laboratory results, previous treatment, current medicines, allergies, surgery history, and the goal you are trying to improve.
If those details are missing, a reliable personal “success rate” cannot be calculated.
Use that as your starting point. We’ll turn it into a clear list of questions so you know what to ask before you commit.
How we can help
We review patient information, verify what’s in the public records, and coordinate communication before you travel to Japan.
Diagnosis, stage, recent reports, imaging, medicines and previous treatment are arranged into a practical summary.
We help match the exact name of the proposed intervention to available MHLW, PMDA and jRCT information.
Cell source, processing, route, number of administrations, price, follow-up and refund terms are separated clearly.
You receive a focused question list so important evidence, safety and cost details are not missed.
We support appointment communication, document preparation, language needs and practical planning for Japan.
We don’t diagnose, prescribe, decide if you’re eligible, or guarantee results. Those calls belong to qualified medical professionals.
Start with what you already have
Diagnosis, stage and when the condition was confirmed.
Recent medical summary, laboratory results and imaging reports.
Current medicines, previous procedures and rehabilitation history.
The exact stem-cell product or procedure name you were offered.
Written quote, consent information or documents you have received.
The regulatory route and public record for the exact intervention.
Human evidence in patients with a diagnosis and stage like yours.
Cell source, processing method, planned dose and administration route.
Known adverse events, emergency plan and scheduled follow-up.
Total course cost, included services and non-refundable stages.
Go deeper only where you need it
Patient questions
Use the exact diagnosis, intervention and written records when comparing answers.
Better info, better decision
Send your existing records or the written proposal you’ve received. We’ll help organize the information, run the public-record checks, and put together the practical questions for your next step.
We provide information review and coordination support. We don’t diagnose, prescribe, decide eligibility, or guarantee outcomes.
